SUNNYVALE, California,
September 20, 2017 /PRNewswire/
--
Accuray Incorporated (NASDAQ: ARAY) announced today that data
and first-hand experience with its advanced CyberKnife® and
Radixact™ Systems , and unique software solutions, will be shared
by leading radiation oncology practitioners at the 2017 ASTRO
(American Society for Radiation Oncology) Annual Meeting in
San Diego, California from
September 24 to 27, 2017.
"We are pleased to have the opportunity to share information
about our products which will benefit clinicians' practice today
and lead to innovations that we anticipate will enhance the way
cancer is treated in the future. We believe that compelling new
data, expert insights and product demonstrations underscore our
focus on putting patients first and at the same time, will
reinforce clinicians' confidence in the value of our technologies
over the long-term," said Lionel Hadjadjeba, MD, Senior Vice
President and Chief Commercial Officer at Accuray.
Meeting highlights: innovations in treatment planning and
delivery
Meeting attendees are invited to visit Accuray booth #1517
throughout the meeting to see software demonstrations, hear from
industry experts and speak with company representatives.
- The CyberKnife System upgrade with the Accuray Precision™
Treatment Planning System (TPS): the fully integrated
Accuray TPS allows clinicians to reduce treatment times, while
advanced TPS features enhance workflow efficiencies.
- The Radixact System: the next generation TomoTherapy®
platform represents a major step forward in treatment speed,
efficiency and ease of use, enabling customers to deliver precise
radiation treatments to a high volume of patients.
- The CyberKnife System High-Definition ImagingRing
(HDI)*: a cutting-edge cone beam CT (CBCT) imaging system
designed to enable both 3D volumetric imaging and adaptive
radiotherapy workflows. When paired with the System's highly
accurate couch imaging and patient registration, along with true
robotic alignment, it is projected to facilitate unmatched
precision and versatility in stereotactic radiosurgery and
stereotactic body radiation therapy. *Work in progress and not
available for sale in any market.
Multiple opportunities to hear from radiation oncology
experts
ASTRO attendees can attend educational symposia and Accuray
Exchange in Radiation Oncology (AERO™) Academy sessions to learn
about advances in clinical practice that are transforming patient
experience and outcomes.
Click here for more information or to register for the
symposia.
CyberKnife System Symposium: Sunday, September
24th from 12:15p.m. PT - 1:15p.m. PT
- Clinical Experience with Breast Applications
Jonathan Haas, MD, Winthrop University Hospital, United States
- Prostate SBRT - Heterogeneous Dose
Distribution: Rationale, Methods, Outcomes and Future
Direction: 2017 Update
Donald B. Fuller, MD, Genesis
Healthcare Partners, United
States
- Head and Neck Skull Base Stereotactic Radiotherapy Plan
Comparison Study: Gamma Knife, CyberKnife®, Linac Photons, or
Protons?
Jack Phan, MD, PhD, MD Anderson
Cancer Center, United
States
Radixact™ System Symposium: Monday, September 25th from
12:30p.m. PT - 1:30 p.m. PT
- TomoTherapy® versus RapidArc: Comparison
of Clinical Outcomes in Head & Neck Cancers
Jean-Emmanuel Bibault, MD, MSc,
Georges Pompidou European Hospital, France
- Adaptive Replanning and Delivery Verification with
PreciseART™ on Radixact™
X. Allen Li, PhD, DABMP, FAAPM,
Medical College of Wisconsin,
United States
- UW Radixact™ Experience
John Bayouth, PhD, University of
Wisconsin -
Madison School of Medicine
and Public Health, United
States
AERO™ Academy Sessions: September
24th - September
26th
Presentations will be hosted on a daily basis at Accuray booth
#1517. Attendees will have the opportunity to engage in interactive
discussions on the real-world use of Accuray technologies with
clinical experts. Topics include CyberKnife prostate SBRT, using
the TomoTherapy System for whole breast irradiation and the
feasibility of real-time motion management with the Radixact
System.
About Accuray
Accuray Incorporated (NASDAQ: ARAY) is a radiation oncology company
that develops, manufactures and sells precise, innovative tumor
treatment solutions that set the standard of care with the aim of
helping patients live longer, better lives. The company's
leading-edge technologies deliver the full range of radiation
therapy and radiosurgery treatments. For more information,
please visit http://www.accuray.com or follow us on Facebook,
LinkedIn, Twitter and YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to clinical applications,
clinical results, patient outcomes, clinician confidence, future
developments of our technologies and Accuray's leadership position
in radiation oncology innovation and technologies. Forward-looking
statements are subject to risks and uncertain-ties that could cause
actual results to differ materially from expectations, including
but not limited to the risks detailed from time to time under the
heading "Risk Factors" in the company's report on Form 10-K, filed
on August 25, 2017, and the company's
other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.